莫西沙星治疗恶性肿瘤合并社区获得性肺炎的疗效观察

Curative effect of moxifloxacin on malignant tumor combined with community-acquired pneumonia

目的研究莫西沙星治疗恶性肿瘤合并社区获得性肺炎（CAP）的疗效和安全性。方法118例恶性肿瘤合并CAP病例随机分为治疗组（60例）和对照组（58例）。治疗组应用莫西沙星治疗，对照组应用左氧氟沙星治疗，观察其疗效和安全性。结果两组总有效率分别是88．3％和62．1％，痊愈率分别是48．3％和34．5％，两组共分离细菌65株，细菌清除率分别为87．9％和62．5%（P〈0.05），不良反应发生率分别为5．0％和10.3％（P〈0.05）。结论莫西沙星治疗恶性肿瘤合并CAP患者临床疗效好，细菌清除率高，使用安全。

Objective To research the curative effect and security of moxifloxacin on malignant tumor with community-acquired pneumonia, Methods 118 patients with malignant tumor combined with community-acquired pneumonia were randomly divided into treatment group （60 cases） and control group （58 cases）. The treatment group and control group were treated with moxifloxacin and levofloxacin, respectively. Then the curative effect and security were observed. Results The total effective rates were 88.3% and 62.1%, cure rates were 48.3% and 34.5% in treatment group and control group, respectively. Totally, the two groups isolated 65 bacterium. The bacterial clearance rates were 87.9 %and 62.5 %, and the incidence of adverse events were 5.0 % and 10.3 %in treatment group and control group, respectively （ P 〈0.05）. Conclusions This study suggests that moxifloxacin is an effective and safe drug with high bacterial clearance rate for treating cancer patients with community-acquired pneumonia.